OptiBiotix Health PLC Presentation of research data
24 January 2017 - 6:01PM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
24 January 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Presentation of research at Microbiome R&D and Business
Collaboration: Asia
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it will be presenting research data
on its microbiome modulators at the Microbiome R&D and Business
Collaboration Congress: Asia, in Hong Kong on the 1-2 March 2017.
The conference brings together experts in all areas of microbiome
research and is recognised around the world as one of theleading
conferences for bringing together pharma, biotech, academic
institutions and investors who are looking to develop and progress
ground-breaking microbiome research into next generation products
through partnering.
OptiBiotix's conference abstract and presentation covers
research which demonstrates the company's ability to create
designer ingredients which can modify an individual's microbiome.
These studies suggest commercial potential for:-
i. The development of species or genera specific prebiotics
which can selectively enhance the growth and health benefits of
existing probiotic products. This new product concept, called an
OptiBiotic(R), has the potential to enhance probiotic health
benefits and provide product differentiation in the probiotic
market, a market forecast to be worth more than $46.5bn by 2020
(Markets and Markets).
ii. Designer ingredients which can modify an individual's
current microbiome to improve health. These ingredients are heat
resistant and stable during processing, which creates the
opportunity to incorporate low cost, safe, ingredients which
modulate specific elements of the microbiome in a wide range of
food products.
Commenting, Stephen O'Hara, CEO of OptiBiotix said: "The ability
to create designer ingredients which can modify an individual's
microbiome to improve health places OptiBiotix at the forefront of
global microbiome research and product development. I believe we
are fast approaching the next stage in the development of the
microbiome in healthcare, where scientists have the ability to
precision engineer components of the microbiome to prevent, manage
and treat many of today's chronic lifestyle diseases."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABRGDBIGDBGRX
(END) Dow Jones Newswires
January 24, 2017 02:01 ET (07:01 GMT)